Tilting a globally diversified portfolio towards ISCV can potentially outperform during factor cycles with AVDV. Click here ...

Despite concerns over cabozantinib's patent expiry, Exelixis projects robust future revenues, with lead pipeline candidate zanzalintinib showing potential to offset future revenue losses.

Caution against over-optimism in the roaring markets of the 2020s, as history warns of potential corrections and emphasizes ...

The S&P 500's recent growth, driven by AI optimism and productivity gains, contrasts extremely extended valuations, creating ...

Learn how Meta Platforms' partnership with eBay could boost user growth, making eBay stock an attractive investment ...

Disney and Fubu reached a merger agreement under which Disney will combine its Hulu + Live TV business with Fubo to create a ...

Dow Inc. has seen a revenue decline, but profit margins improved from 2% to 3.6% in the first nine months of 2024. Learn more ...

Analysis of Coloplast's growth potential and concerns for Q1'25, including margin misses and slow share growth in the U.S.

Medpace offers a potential opportunity with a current 28 P/E ratio yet better future earnings growth. Click here to read an ...

Seanergy Maritime Holdings offers strong revenue growth and high RoE, making it an attractively priced investment opportunity ...

The Morningstar Wide Moat Focus Index retreated along with the broad U.S. equity market in December, falling 4.5% during the ...

Northern Technologies International's Q1 results showed bioplastics growing, industrial segments flat. Click here to read why ...